Related Articles
Cancer
Targeting HER2 mutations in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Read more
Cancer
Researching DLL3-positive carcinoma
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Read more
Cancer
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology highlighting our cancer research and how we are driving innovation to deliver meaningful advances to people with cancer.
Read more